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ABSTRACT
Combined modality therapy emerged from preclinical
data showing that carefully chosen drugs could enhance
the sensitivity of tumor cells to radiation while having
nonoverlapping toxicities. Recent advances in molecu-
lar biology involving the identification of cellular recep-
tors, enzymes, and pathways involved in tumor growth
and immortality have resulted in the development of bi-
ologically targeted drugs. This review highlights the re-
cent clinical data in support of newer generation
cytotoxic chemotherapies and systemic targeted agents
in combination with radiation therapy. The Oncologist
2010;15:372–381
INTRODUCTION
Radiation therapy (RT) is used to control locally confined
tumors with organ preservation. The ability of radiation
alone to control soft tissue tumors is often limited by the
tumor volume or the surrounding normal tissue tolerance to
radiation. Cytotoxic chemotherapy drugs and biologic
agents have been given before, during, or after RT in order
to improve tumor responses. Neoadjuvant or induction che-
motherapy can be employed to decrease micrometastases
and decrease tumor size prior to RT with the hopes of im-
proving tumor control with RT and/or decreasing the
amount of normal tissue irradiated. Adjuvant chemother-
apy is given after RT primarily to decrease systemic micro-
metastases. Concurrent chemoradiotherapy (chemo-RT)
emerged from preclinical data showing that carefully cho-
sen drugs could enhance the sensitivity of tumor cells to RT
while having nonoverlapping toxicities. This spatial coop-
eration was the initial rationale for combining chemother-
apy and RT, in which each agent had an independent
mechanism of action at a different anatomic target. Since
that time, concurrent chemoradiation has been used to en-
hance radioresponse locally within the primary tumor.
Here, we review the recent clinical data in support of newer
generation cytotoxic chemotherapies and systemic targeted
agents in combination with RT.
Combined modality therapy enhances RT or systemic
therapies alone at both the tissue and cellular levels. At a
tissue level, radiation can increase vascular permeability
and allow greater drug delivery to the tumor as well as in-
crease drug concentration by promoting drug retention
within the tumor. At a cellular level, systemic therapies can
enhance radiation sensitivity by inhibiting DNA repair
mechanisms, enhancing oxygen radical formation to pro-
mote DNA double strand breaks, inhibiting progression
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through the cell cycle to lock cells in a radiosensitive phase,
inducing apoptosis, and inhibiting cellular signaling cas-
cades. Recent advances in molecular biology involving the
identification of cellular receptors, enzymes, and pathways
involved in tumor growth and immortality have resulted in
the development of biologically targeted drugs. The use of
targeted therapies in conjunction with RT promises to en-
hance the therapeutic ratio by increasing the efficacy of RT
without significantly increasing treatment-related side ef-
fects. As individual tumor mutations and molecular mark-
ers are better understood, it may also be possible to improve
patient selection by determining which patients will benefit
from a given agent. (See Table 1.)
It is appropriate to have an article on combined modality
therapy in this issue, because Dr. Glatstein (or Eli, as we
shall call him; he has never stood for the formality of being
called Dr. Glatstein during the standard work day) felt that
an important part of the reason he had been brought to the
National Cancer Institute (NCI) was to “marry NCI chemo-
therapy with Stanford radiation therapy.” When the senior
author started his residency in radiation oncology with Eli
in 1984, “combined modality” for lymphomas, a major em-
phasis at the NCI, meant chemotherapy first, followed by
RT. We had a particularly intensive study for advanced-
stage follicular lymphoma that involved full-dose chemo-
therapy with a nine-drug myelosuppressive regimen
followed by total nodal radiation. After all that chemother-
apy, the patients’ counts would drop after the dose deliv-
ered by simulation and would vaporize after the first week
of treatment. It would take us months to get patients through
this. In contrast, local toxicities (esophagitis and pneumonitis)
dominated the treatment of limited-stage small cell lung can-
cer with concurrent aggressive chemotherapy and RT. Eli was
among the early users of “adaptive therapy.” Treatment with
chemoradiation would start on Monday, and we would re-
simulate patients every Friday in order to shrink the fields.
(The total course was a spicy 40 Gy in 15 fractions with con-
current doxorubicin-containing chemotherapy!) Combined
modality therapy was superior, but there was significant mor-
bidity and even mortality from treatment.
CYTOTOXIC CHEMOTHERAPY
The Platins
Cisplatin is one of the most commonly used chemother-
apy agents for radiosensitization. It forms both inter- and
intrastrand DNA adducts that produce single-strand
breaks when removed by DNA mismatch repair processes.
These single-strand breaks can be converted to lethal dou-
ble-strand breaks by radiation. Thus, mismatch repair de-
fective cells are not radiosensitized by cisplatin and
carboplatin [1]. Phase III trials have proven longer survival
times for patients treated with concurrent cisplatin-based
chemo-RT than for those treated with RT alone in cervical
cancer, head and neck cancer, non-small cell lung cancer
(NSCLC), and esophageal cancer.
Oxaliplatin is a third-generation platinum derivative
that has been found to be a potent radiosensitizer [2]. It is a
diaminocyclohexane that causes DNA adduct formation
and prevents DNA synthesis [3]. Although oxaliplatin ap-
pears to cause DNA adduct formation like other platinum
derivatives, oxaliplatin adducts are not repaired by the same
DNA mismatch repair systems as other platinum adducts.
Oxaliplatin, therefore, has been found to have activity in
cisplatin- and carboplatin-resistant cells [4, 5].
Oxaliplatin results in longer survival times in meta-
static colorectal cancer patients in combination with
5-fluorouracil (5-FU) than with 5-FU alone [6]. Oxali-
platin is under investigation in phase I/II studies in com-
bination with RT and 5-FU or capecitabine for the
neoadjuvant treatment of rectal cancer patients, with an
81% rate of R0 resection. The pathologic complete re-
sponse rate has been in the range of 8%–26%, with rates
of grade 3 or 4 diarrhea of 16%–38% [7–9]. Phase III
studies need to be conducted prior to endorsing the rou-
tine use of oxaliplatin with concurrent RT.
Table 1. Disease sites for which newer cytotoxic
chemotherapy or targeted agents are currently under
investigation concurrently with radiation
Therapy/Agent Disease Sites
Cytotoxic chemotherapies
Oxaliplatin Rectal cancer
5-FU/capecitabine Rectal cancer, pancreatic
cancer
Gemcitabine Pancreatic cancer, NSCLC
Paclitaxel NSCLC, SCC of head and
neck
Temozolomide High grade glioma, brain
metastases
Targeted therapies
Cetuximab NSCLC, SCC of head and
neck, pancreatic cancer
Gefitinib NSCLC, SCC of head and
neck
Erlotinib Rectal cancer, GBM,
NSCLC
Bevacizumab Rectal cancer, GBM,
NSCLC, pancreatic cancer
Abbreviations: GBM, glioblastoma multiforme; NSCLC,
non-small cell lung cancer; SCC, squamous cell
carcinoma.
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5-FU and Capecitabine
5-FU is a pyrimidine analog of uracil and functions as an
antimetabolite. Its radiosensitizing effects are a result of its
ability to prevent DNA synthesis through inhibition of thy-
midylate synthase [10], rather than its RNA-dependent ef-
fects. The combination of 5-FU and RT was superior to RT
alone in randomized trials for patients with head and neck
and gastrointestinal (GI) cancers, including esophageal,
gastric, pancreatic, and rectal cancers.
Capecitabine is an oral 5-FU prodrug; it is converted to
5-FU by the enzyme thymidine phosphorylase (TP). TP cat-
alyzes the mutual transformation of the pyrimidine nucleo-
sides thymidine and thymine in nucleic acid metabolism
and also converts the FU-based drugs, including capecitab-
ine, into active 5-FU. It is, therefore, a limiting factor of the
mechanism of action for capecitabine. A proposed mecha-
nism of selectivity is the preferential conversion in the liver,
which is relatively resistant, and at the tumor site, because
these tissues often have higher TP activity than normal
tissue.
RT was reported to lead to better efficacy with capecit-
abine through tumor-associated induction of TP, especially
within the radiation portal. However, this was not found to
be consistently true in other preclinical studies of colon can-
cer cells [11], in tumor xenografts [12], or in a phase I dose-
escalation study from the University of Alabama [13].
Although these results support the concurrent use of cape-
citabine and RT in pancreatic cancer, there appear to be ad-
ditional genes (other than TP) associated with response to
capecitabine alone and with RT.
Because of its ease of administration compared with
continuous infusion 5-FU, attempts have been made to sub-
stitute capecitabine for infusional 5-FU in combination
with RT in pancreatic cancer and rectal cancer patients [14,
15]. We are unaware of any head-to-head comparisons of
infusional 5-FU versus capecitabine, but our overall im-
pression is that these are probably approximately equiva-
lent.
Gemcitabine
2,2-Difluoro-2-deoxcytidine, or gemcitabine, requires
intracellular phosphorylation in a rate-limiting step by
deoxycytidine kinase to form its active metabolites dif-
luorodeoxycytidine diphosphate (dFdCDP) and difluoro-
deoxycytidine triphosphate (dFdCTP). These metabolites
of gemcitabine produce two distinct mechanisms of action
contributing to gemcitabine’s radiosensitizing and cyto-
toxic properties, respectively. DFdCDP is a direct inhibitor
of ribonucleotide reductase and thus inhibits deoxynucle-
otide triphosphate synthesis whereas dFdCTP is incorpo-
rated into DNA, both leading to the inhibition of DNA
synthesis. Early preclinical studies demonstrated that gem-
citabine was an effective radiosensitizer in a variety of cell
types [16, 17]. Subsequent studies investigating the mech-
anism(s) of radiosensitization suggested that dATP pool de-
pletion (via ribonucleotide reductase inhibition) as well as
redistribution of cells into the early S-phase of the cell cycle
underlie gemcitabine-mediated radiosensitization [18].
Based on the observed preclinical radiosensitization by
gemcitabine as well as the clinical efficacy of gemcitabine
as a single agent, gemcitabine has been combined with RT
in the clinic to treat many solid tumor types.
Gemcitabine has become the standard of care for meta-
static pancreatic cancer [19]. We feel it has become a stan-
dard component for locally advanced disease. In this latter
group, a recent trial phase III trial of 74 patients with unre-
sectable pancreatic cancer randomized patients to either
gemcitabine or gemcitabine and concurrent RT, showing a
statistical survival advantage for patients in the chemo-RT
arm (11 months versus 9.2 months; p  .04), but higher GI
and hematologic toxicity rates in the chemo-RT arm [20]. A
French phase III trial of induction chemo-RT followed by
gemcitabine was compared with gemcitabine alone, show-
ing the chemo-RT arm to be more toxic and less effective
than gemcitabine alone. The 1-year overall survival rates
were 32% versus 53% favoring gemcitabine alone [21]. In
that trial, however, patients in the chemo-RT arm had sig-
nificantly shorter survival than historical controls. This
could be because concurrent, high-dose gemcitabine and
RT is toxic when large radiation fields are used [22]. How-
ever, the use of conformal radiation to the primary tumor
site without elective nodal radiation permits the safe admin-
istration of full systemic doses of gemcitabine or gemcitab-
ine plus oxaliplatin [23, 24]. Although Eli has been noted to
say, “Local control does not guarantee immortality,” local
failure does occur in these patients [25] and can be the cause
of death. This has motivated our recent attempts to dose es-
calate radiation using intensity-modulated RT with full-
dose gemcitabine. Results are promising, with a median
survival duration of 23 months [26].
In a phase III trial of adjuvant therapy for locally ad-
vanced resected pancreatic cancer, the addition of adjuvant
gemcitabine after 5-FU and concurrent RT showed longer
survival than with 5-FU and RT alone for patients with pan-
creatic head tumors [27]. Although a phase I/II study
showed that concurrent full-dose gemcitabine and RT can
be given safely as adjuvant treatment [28], it is not known
whether this combination is superior to the more commonly
used 5-FU or capecitabine plus RT combination.
Phase I/II studies have also evaluated the role of gem-
citabine (alone or in combination with a platinum or pacli-
taxel) and concurrent RT in locally advanced NSCLC
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patients. Preliminary data have shown high rates of pulmo-
nary toxicity, although gemcitabine, at a dose of 150 mg/
m2, was tolerated in the setting of three-dimensional (3D)
RT planning [29–33]. Caution is advised when gemcitab-
ine is given with concurrent RT because of gemcitabine’s
enhanced radiosensitization effects in the lung and esopha-
gus, and appropriate chemotherapy doses have not been
well established.
Paclitaxel
The taxanes are mitotic spindle inhibitors that bind to the
N-terminal amino acid in -tubulin and stabilize tubulin
polymers, thereby promoting microtubule assembly and in-
hibiting disaggregation [34]. This action causes cellular ar-
rest in G2/M, the most radiosensitive phase of the cell cycle.
Paclitaxel is the most commonly used taxane in combina-
tion with RT and appears to act by causing mitotic arrest
and inducing apoptosis, and also may also induce reoxy-
genation within the tumor [35, 36].
Paclitaxel has been used in combination with carbopla-
tin currently with RT in the setting of locally advanced
NSCLC because it was thought to have a favorable toxicity
profile. Initially, concurrent chemo-RT with cisplatin and
etoposide was found, in trials, to be superior to sequential
therapy in unresectable NSCLC patients [37]. Phase II data
then showed that RT with low-dose weekly concurrent pac-
litaxel plus carboplatin and induction or paclitaxel plus car-
boplatin was feasible [38, 39]. Specifically, the Cancer and
Leukemia Group B (CALGB) initially evaluated the com-
bination of induction carboplatin and paclitaxel for two
cycles followed by low-dose weekly concurrent chemo-
therapy with RT. They found a median survival time of 15.1
months, and the trial demonstrated the feasibility of this
regimen [39]. A phase III trial, CALGB 39801, was then
completed, in which all patients received low-dose weekly
carboplatin and paclitaxel with concurrent RT to 66 Gy and
were randomized to two cycles of induction chemotherapy.
Both arms of that trial showed disappointing results, with a
median survival time of 11–13 months, demonstrating that
this was not an efficacious regimen [40]. The CALGB
30105 trial evaluated induction chemotherapy followed by
concurrent carboplatin, paclitaxel, and RT or concurrent
carboplatin, gemcitabine, and RT in stage IIIA/IIIB
NSCLC patients. Both arms required 3D RT planning, and
all patients received 74 Gy. They found that patients in the
paclitaxel arm had a median overall survival time of 24
months whereas the gemcitabine arm was closed early sec-
ondary to a high rate of grade 4 or 5 pulmonary toxicity. The
hypothesis generated by that trial is that the longer median
survival time seen in the carboplatin–paclitaxel arm was a
result of the higher RT dose [36].
To date, carboplatin and paclitaxel have not been com-
pared with cisplatin-based chemo-RT, which continues to
be considered the standard as definitive or neoadjuvant
treatment in NSCLC patients.
In locally advanced and unresectable head and neck
cancer, paclitaxel has been used concurrently with RT. The
Eastern Cooperative Oncology Group (ECOG) E2399
study was a phase II trial of induction carboplatin plus pac-
litaxel followed by concurrent carboplatin, paclitaxel, and
RT for patients with resectable stage III/IV squamous cell
carcinoma of the larynx and oropharynx. That study
showed an 81% organ preservation rate overall at 2 years,
with a higher organ preservation rate in oropharynx pa-
tients, and the regimen was well tolerated [41]. Another
phase II trial in unresectable head and neck cancer patients,
including all sites, showed that RT with concurrent weekly
carboplatin plus paclitaxel was well tolerated, but 42% of
patients (n  50) had some component of locoregional fail-
ure at 5 years, and the overall survival rate was 35% [42].
Chougule et al. [43] conducted a trial of concurrent carbo-
platin plus paclitaxel and RT, demonstrating a 91% re-
sponse rate with a 26% locoregional failure rate in locally
advanced head and neck cancer patients. This regimen,
however, required that 31% of patients be hospitalized be-
cause of toxicity. Salama et al. [44] conducted a phase I/II
trial at the University of Chicago using induction carbopla-
tin and paclitaxel followed by concurrent carboplatin, pac-
litaxel, fluorouracil, and hydroxyurea and twice daily RT in
stage III/IV head and neck cancer patients, showing a high
locoregional control rate and overall survival rate of 91%
and 62%, respectively, at 5 years. Ninety-one percent of pa-
tients experienced grade 3 or 4 acute toxicity during chemo-
RT. As in locally advanced NSCLC patients, concurrent
carboplatin and paclitaxel regimens with RT have not been
prospectively compared with cisplatin-based chemo-RT in
locally advanced head and neck cancer patients.
Temozolomide
Temozolomide is an orally administered alkylating agent
that induces apoptosis by methylation of DNA at nucleo-
philic sites, causing the formation of O6-methylguanine.
This DNA adduct induces futile cycling of the mismatch
repair pathway, but the adduct can also be repaired by
the enzyme O6-methylguanine-DNA methyltransferase
(MGMT). Patients with high levels of MGMT methylation,
which indicates that the gene has been silenced, have longer
progression-free and overall survival times after treatment
with alkylating agents [45].
In preclinical studies, temozolomide was found to have
schedule-dependent activity against recurrent high-grade
gliomas and advanced melanoma, to have oral bioavailabil-
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ity, and to penetrate the central nervous system [46, 47]. Its
use in the concurrent setting with RT is largely based on
early clinical data supporting a small advantage over cur-
rent treatment at that time. A large phase II trial of temozo-
lomide versus procarbazine in recurrent glioblastoma
multiforme (GBM) patients demonstrated a significant
6-month progression-free and overall survival advantage
for patients treated with temozolomide as a single agent,
with similar toxicity [48]. Following this, a pilot phase II
trial of concurrent temozolomide and RT followed by adju-
vant temozolomide was then conducted, demonstrating a
promising overall survival rate at 2 years of 31% [49]. Con-
current temozolomide and RT followed by temozolomide
alone in GBM was then studied in a large phase III trial and
found to result in longer survival versus RT alone [50],
thereby establishing the standard of care.
Temozolomide with concurrent RT is currently being
investigated for patients with high-risk, low-grade gliomas
(Radiation Therapy Oncology Group [RTOG] 0424 trial).
Additionally, temozolomide is being examined for use with
concurrent RT in the setting of brain metastasis. A phase II
single-institution trial of whole-brain RT and concurrent as
well as adjuvant temozolomide in 27 patients with at least
one brain metastasis from breast cancer or NSCLC revealed
complete and partial response rates of 7% and 41%, respec-
tively. The regimen was well tolerated [51]. RTOG 0320 is
a phase III trial that is under way investigating whole-brain
RT and stereotactic radiosurgery alone versus the same ra-
diation with concurrent temozolomide or erlotinib.
MOLECULAR TARGETED THERAPIES
Epidermal Growth Factor
Receptor–Directed Therapies
The human epidermal growth factor receptor (EGFR) fam-
ily includes EGFR, human epidermal growth factor recep-
tor 2 (HER-2), HER-3, and HER-4. (See Figure 1.) EGFR
family members have been identified to play a critical role
in development, progression, and resistance to chemo-RT
in NSCLC, colorectal cancer, pancreatic cancer, squamous
cell carcinoma of the head and neck, brain cancer, and
breast cancer. Additionally, EGFR is either overexpressed
or hyperphosphorylated in the majority of cancers of epi-
thelial origin. Several clinical studies have suggested that
EGFR expression is a powerful prognostic factor for re-
sponse to both RT and chemo-RT. In a retrospective re-
view, Kumar et al. [52] found that a high EGFR expression
level predicts poor response to therapy and poor overall sur-
vival in head and neck cancer patients. Similarly, Pivot et
al. [53] found that lower EGFR levels predicted better dis-
ease-free survival in patients with laryngeal and hypopha-
ryngeal cancers treated with induction chemotherapy
followed by RT. The idea that blocking these receptors pro-
duces selective response in tumors driven by these mole-
cules has led to the development of several monoclonal
antibodies (mAbs) and small molecules that inhibit receptor
kinase activity [54].
Cetuximab
Cetuximab binds to the EGFR with approximately tenfold
greater affinity than the mouse mAb C225 from which it is
derived. Cetuximab not only blocks EGF-induced auto-
phosphorylation of the EGFR but also induces its internal-
ization and degradation, which may contribute to the
outcome of treatment. It has also been reported that cetux-
imab inhibits nuclear translocation of EGFR, which may be
particularly effective in combination with RT, because nu-
clear EGFR can induce DNA protein kinase activity, lead-
ing to efficient DNA repair. Therefore, inhibition of EGFR
is considered an excellent target for radiosensitization. Still,
many aspects of this therapy have yet to be elucidated. For
example, only modest radiosensitization in cultured cells
can be achieved via EGFR inhibitors, and even this requires
prolonged inhibition of EGFR phosphorylation. However,
xenograft data show much more promising results; the
cause of this difference is not yet clearly understood. It has
been postulated that, in addition to blocking direct effects
on EGFR, cetuximab may have effects on cell cycle redis-
tribution, angiogenesis, and immune reaction. This argu-
ment is supported by clinical findings suggesting that: (a)
cetuximab can produce a response in tumors with negative
EGFR staining by immunohistochemistry and (b) the
strength of the EGFR staining does not predict response to
EGFR inhibitors combined with chemotherapy. Although
we cannot yet predict patient response based on the pres-
ence or absence of the target itself, recent findings suggest
that patients carrying a KRAS mutation do not benefit from
treatment with anti-EGFR agents.
A randomized trial in locally advanced head and neck
cancer patients demonstrated that patients receiving the
combination of RT and cetuximab had a statistically signif-
icant better locoregional disease response without signifi-
cantly worse acute toxicities [55]. This is the first study to
show that the combination of a molecularly targeted ther-
apy with RT can result in better local control and survival
than with RT alone. Based on this success, the addition of
cetuximab to concurrent chemo-RT as definitive treatment
in locally advanced head and neck cancer patients is cur-
rently being investigated in the RTOG 0522 study. In the
postoperative setting, RTOG 0234 is a phase II trial now
closed to accrual that evaluated cetuximab with concurrent
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chemo-RT for patients with head and neck cancer and high-
risk pathologic features.
In NSCLC patients, preliminary phase II studies have
shown that cetuximab can be safely administered with RT
and that this does not appear to lead to higher rates of acute
treatment toxicities. The SCRATCH trial, a phase II trial in
stage III NSCLC patients treated with weekly cetuximab
and thoracic RT to 64 Gy demonstrated acceptable toxicity
for this regimen [56]. The Non-small cell lung cancer, Er-
bitux And Radiotherapy (NEAR) trial is an ongoing, phase
II, feasibility trial of concurrent locoregional RT and cetux-
imab in stage III NSCLC patients [57].
Cetuximab in combination with gemcitabine and RT
has been assessed in pancreatic cancer. A randomized
phase II trial was conducted in inoperable patients receiving
gemcitabine, cetuximab, and RT, who then were random-
ized to adjuvant gemcitabine or adjuvant gemcitabine plus
cetuximab. No statistical difference was seen between
arms; the 2-year overall survival rate was 20% [58]. This
result is not surprising; the presence of mutated RAS in
90% of pancreatic cancer cases suggests that EGFR inhi-
bition is unlikely to be successful [59].
Gefitinib and Erlotinib
Gefitinib and erlotinib are small molecule tyrosine kinase
inhibitors used clinically. They inhibit unregulated EGFR
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Figure 1. The effects of radiation, chemotherapy, and targeted agents on EGFR signaling. After stimulation by irradiation or
certain chemotherapeutic agents, epidermal growth factor receptor (EGFR) can activate downstream signaling pathways that can
promote cell survival or cell death. In addition to stimulating the pathways activated by epidermal growth factor (EGF), radiation
can trigger the translocation of phosphorylated EGFR (pEGFR) into the nucleus. This process coincides with the transport of
Ku70/80 and protein phosphatase 1 into the nucleus (not shown), which results in increases in DNA-dependent protein kinase
(DNAPK) levels, the repair of DNA-strand breaks, and cell survival. Cetuximab blocks nuclear transport of pEGFR; it binds to
EGFR and causes endosome internalization, ultimately causing receptor degradation and cell death. Gefitinib and erlotinib bind to
the intracellular ATP binding site of EGFR, thereby inhibiting unregulated EGFR signaling. Gemcitabine causes the phosphory-
lation of EGFR. In this case, EGFR phosphorylation initially activates Akt promoting cell survival, but subsequently promotes the
ubiquitination (Ub) of the receptor, which leads to its degradation along a proteosome or lysosome pathway. pEGFR degradation
results in the downregulation of the survival signal pAkt, leading to apoptosis. Blocking EGFR degradation at various steps of this
pathway reduces gemcitabine-mediated cytotoxicity. Whether an EGFR-activating insult leads to cell survival or cell death might
ultimately be determined by the severity and duration of the stress.
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signaling by binding to the intracellular ATP binding site,
which prevents tyrosine kinase activity.
Recent data have demonstrated that schedule plays a
critical role in the interaction between gefitinib and erlo-
tinib with chemotherapy and with RT. When given prior to
gemcitabine and cisplatin, gefitinib and erlotinib antago-
nize chemotherapy toxicity, whereas the small molecule ty-
rosine kinase inhibitors produce substantial synergy when
given after cytotoxic chemotherapy [37, 60]. The molecular
mechanism for this schedule dependence is now under-
stood. Both gemcitabine and cisplatin cause initial EGFR
phosphorylation, followed by EGFR degradation and cell
death. Therefore, giving an EGFR inhibitor prior to chemo-
therapy blocks this initial phosphorylation, inhibits degra-
dation, and increases survival. Indeed, this is likely the
explanation for the negative results of the Iressa NSCLC
Trial Assessing Combination Treatment (INTACT)-1 and
INTACT-2 studies [61, 62], and a recent clinical trial that
prospectively used chemotherapy followed by small mole-
cule tyrosine kinase inhibition has produced promising re-
sults [63]. In contrast, administration of an EGFR inhibitor
after chemotherapy-induced EGFR phosphorylation poten-
tiates degradation and the subsequent cytotoxicity. A cor-
ollary of the hypothesis that EGFR degradation causes
cytotoxicity is that a proteosome inhibitor such as bort-
ezomib might antagonize chemo-RT by inhibiting EGFR
degradation. In addition, we have recently shown that
EGFR-driven log-phase and plateau-phase cells have a dra-
matically different response to an EGFR inhibitor com-
bined with radiation. A brief (2 hours) pretreatment with
erlotinib can protect plateau-phase EGFR-expressing cells
from radiation by inhibiting EGFR activation, thus prevent-
ing cells from being driven into a fatal S phase after radia-
tion [64]. In contrast, long-term exposure (24 hours) of log-
phase cells to EGFR inhibition ultimately arrests cells in
late G1, which is a relatively sensitive phase of the cell cy-
cle. These findings demonstrate the importance of schedule
and cell cycle in the response to combination treatment with
RT, chemotherapy, and EGFR inhibitors.
Gefitinib has been used in phase I/II trials with RT in
NSCLC and head and neck cancer patients. In stage III
NSCLC patients, a phase II trial of induction carboplatin,
paclitaxel, and irinotecan followed by chemo-RT to 74 Gy
with concurrent carboplatin, paclitaxel, and gefitinib (250
mg daily) showed that the regimen was well tolerated, but
disappointing results of a 24% partial response rate and me-
dian OS time of 16 months were reported [65]. In stage III
and IV head and neck cancer patients, a phase II trial using
two cycles of neoadjuvant carboplatin and paclitaxel fol-
lowed by concurrent RT, 5-FU, hydroxyurea, and gefitinib
showed an estimated 2 year overall survival rate of 83%
with a low rate of grade 4 toxicities [66].
Erlotinib has been combined with RT in the phase I/II
setting in rectal cancer, glioma, and NSCLC patients, for
which EGFR expression is commonly seen. Erlotinib was
tried in a dose-escalation study of patients with locally ad-
vanced or recurrent rectal cancer with concurrent RT, dem-
onstrating excellent local control but only a 5% pathologic
complete response rate at a maximum-tolerated dose of 100
mg daily for 45 days [67]. In GBM patients, the North Cen-
tral Cancer Treatment Group reported a phase I/II trial in
which patients received concurrent RT, temozolomide, and
erlotinib. The regimen was well tolerated, but the median
survival time of 15.3 months did not show an advantage
over historic controls in the European Organization for Re-
search and Treatment of Cancer 26981 study [52].
It is noteworthy that despite the high frequency of mu-
tant RAS in pancreatic cancer and lack of difference in re-
sponse with cetuximab, erlotinib is the only molecularly
targeted agent shown thus far to result in statistically longer
survival in patients with advanced disease treated with
gemcitabine [69].
Bevacizumab
Expression of angiogenic factors is required for tumor
growth, and the most commonly studied factor is vascular
endothelial growth factor (VEGF). Bevacizumab is a
monoclonal antibody that binds to the VEGF receptor on
the extracellular surface and is thought to normalize tumor
vasculature, thereby potentially allowing enhanced oxygen
and chemotherapy drug delivery locally. In rectal cancer,
bevacizumab has been found to have antivascular effects,
decreasing perfusion and intrastitial fluid pressure within
the tumor [70]. In locally advanced rectal cancer, phase I
and II trials have been conducted to evaluate the addition of
bevacizumab to neoadjuvant therapy. When bevacizumab
was added to neoadjuvant capecitabine and RT for locally
advanced rectal cancer, the pathologic complete response
rate was 32%, with a 72% sphincter preservation rate and
no grade 3 GI or hematologic toxicities [71].
Bevacizumab is also under investigation with concur-
rent RT in the treatment of GBM patients. Preliminary
phase II data with concurrent temozolomide and RT have
shown that the regimen is well tolerated without a higher
rate of acute toxicity [72].
Bevacizumab has also been evaluated with gemcitabine
and RT in locally advanced pancreatic cancer patients. This
regimen is now approached with caution, however, because
of high toxicity manifest as surgical complications and ul-
ceration or bleeding in the radiation field [73–75].
Despite some encouraging results for bevacizumab plus
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RT in small trials, there is no current recognized role for this
therapy off protocol.
FUTURE DIRECTIONS
How can we best build on our knowledge of chemo-RT to
design more effective combinations (with and without tar-
geted therapies)? First, we feel that preclinical data may
guide us in optimizing therapy and patient selection. For in-
stance, preclinical studies show that it is possible for tar-
geted therapies that block cell cycle progression (such as
cetuximab) to antagonize some chemotherapies that depend
on cell cycle progression (such as gemcitabine) [76]; it is
possible that such effects may explain some of the negative
results seen in adding targeted therapies to lung cancer
treatment [77]. In another example, targeted therapies have
typically been tested in unselected populations or, even
worse, in populations in which preclinical data suggest that
the patient population will be resistant to the therapy (erlo-
tinib in pancreatic cancer, which commonly displays RAS
mutations). It is possible that the addition of RT could alter
signaling pathways so that these issues don’t matter, but
this is speculation.
A second possible focus for improvement would be to
devote more attention to determining if the target is actually
being hit. The senior author learned this directly from Eli
during his residency, during which special efforts were
made to obtain tumor and bone marrow biopsies to deter-
mine incorporation of the radiation sensitizers iododeoxy
and bromodeoxyuridine. These studies are difficult, to be
sure, but an understanding of how, for instance, cetuximab
affects downstream signaling in tumors from even four to
six patients might provide us with more understanding
about how to optimize this agent in combination with RT or
chemo-RT than a randomized phase II trial of 100 un-
selected patients without pharmacodynamic studies.
Third, we feel that these studies suggest a role for highly
conformal RT to enable the use of chemotherapy and tar-
geted therapies. We can’t discuss this without bringing Eli
into the picture. Eli has been unfairly characterized as
“anti-technology”; in fact, he (and we) are opposed to the
mindless application of technology that, sadly, often char-
acterizes our field. Highly conformal therapy, which ex-
cludes clinically uninvolved regions, can permit full doses
of chemotherapy and targeted therapies to be administered
safely. Eli has been known to complain that radiation on-
cologists and medical oncologists are sometimes engaged
in “a battle for the last megakaryocyte.” The increasing use
of conformal RT and targeted therapies will, we hope, re-
place this battle with a collaboration over how to cure pa-
tients while treating acne and mild diarrhea.
Finally, we feel that these developments give the oppor-
tunity to expand the scope of practice of the radiation on-
cologist, and, here too, we celebrate Eli’s lead. Eli always
told his trainees that we are not “modality salesmen” but we
need to be oncologists and physicians. Indeed, he would say
that radiation oncologists are the only physicians who are
consistently called on to treat both early-stage disease (like
the surgeon) and metastatic disease (like the medical oncol-
ogist). During his medical oncology training, the senior au-
thor was struck by how much of his training was focused on
ameliorating the toxicity of chemotherapy. The introduc-
tion of far less toxic targeted therapy permits the radiation
oncologist to lead efforts to develop new radiation sensi-
tizer strategies, as part of multidisciplinary care, without
subjecting patients to severe toxicity.
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